Browse Studies — Arctuva

Phase 2

A Phase II Trial of the MEK Inhibitor Mirdametinib in Histiocytic Disorders

The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be …

Langerhans Cell Histiocytosis (LCH)Juvenile Xanthogranuloma (JXG)Rosai-Dorfman Disease (RDD)+1 more

Estimated

~$10 – $5,625

Children's Hospital Medical Center, CincinnatiNCT06153173

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic maligna…

Hematologic MalignanciesInherited Disorders of MetabolismInherited Abnormalities of Platelets+14 more

Estimated

~$10 – $1,125

Center for International Blood and Marrow Transplant ResearchNCT01351545

International Rare Histiocytic Disorders Registry (IRHDR)

The rare histiocytic disorders (RHDs) are characterized by the infiltration of one or more organs by non-LCH histiocytes. They can range from localized disease…

Rare Histiocytic Disorders (RHDs)Erdheim-Chester Disease (ECD)Rosai-Dorfman Disease (RDD)+7 more

Estimated

~$10 – $750

The Hospital for Sick ChildrenNCT02285582

Phase 2

A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders.

This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorder…

Langerhan's Cell HistiocytosisJuvenile XanthogranulomaErdheim-Chester Disease+4 more

Estimated

~$10 – $7,500

Carl AllenNCT04079179